Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miglitol versus acarbose in newly diagnosed overweight or obese type 2 diabetes
ChiCTR2000030267Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2020
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Miglitol treatment group with Acarbose treatment group (2 arms). Primary endpoint: HbA1c. Started Mar 2020; status: recruiting.
02
Drugs
miglitolacarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000030267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030267.